S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.32%)
NIO   7.43 (+1.50%)
BABA   72.38 (-0.89%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.23 (-1.07%)
DIS   90.79 (-1.33%)
AMC   7.02 (-6.28%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.32%)
NIO   7.43 (+1.50%)
BABA   72.38 (-0.89%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.23 (-1.07%)
DIS   90.79 (-1.33%)
AMC   7.02 (-6.28%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.32%)
NIO   7.43 (+1.50%)
BABA   72.38 (-0.89%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.23 (-1.07%)
DIS   90.79 (-1.33%)
AMC   7.02 (-6.28%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.32%)
NIO   7.43 (+1.50%)
BABA   72.38 (-0.89%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.23 (-1.07%)
DIS   90.79 (-1.33%)
AMC   7.02 (-6.28%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Turnstone Biologics Stock Price, News & Analysis (NASDAQ:TSBX)

$2.71
-0.28 (-9.36%)
(As of 04:00 PM ET)
Compare
Today's Range
$2.61
$3.00
50-Day Range
$1.80
$3.94
52-Week Range
$1.63
$13.20
Volume
132,293 shs
Average Volume
88,430 shs
Market Capitalization
$62.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Turnstone Biologics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
601.1% Upside
$19.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.45) to ($3.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

748th out of 949 stocks

Biological Products, Except Diagnostic Industry

119th out of 149 stocks


TSBX stock logo

About Turnstone Biologics Stock (NASDAQ:TSBX)

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

TSBX Stock Price History

TSBX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Turnstone Biologics price target lowered to $15 from $18 at BofA
Turnstone Biologics GAAP EPS of -$1.00
Turnstone Biologics GAAP EPS of $1.00
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Turnstone Biologics Corp TSBX
Turnstone Biologics Corp.
Turnstone Biologics Corp
Turnstone Biologics Corp (TSBX)
See More Headlines
Receive TSBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/08/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TSBX
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$20.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+601.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-30,830,000.00
Pretax Margin
-176.53%

Debt

Sales & Book Value

Annual Sales
$73.30 million

Miscellaneous

Free Float
N/A
Market Cap
$62.57 million
Optionable
Not Optionable
Beta
N/A
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Sammy J. Farah M.B.A. (Age 51)
    Ph.D., President, CEO & Director
    Comp: $678.51k
  • Dr. Venkat Ramanan Ph.D. (Age 54)
    Chief Financial Officer
    Comp: $346.13k
  • Dr. Michael F. Burgess M.D. (Age 60)
    MBChB, Ph.D., Interim Chief Medical Officer & Executive Director
    Comp: $212.69k
  • Ms. Saryah Azmat (Age 34)
    Chief Business Officer
    Comp: $479.73k
  • Dr. Vijay Chiruvolu M.B.A. (Age 61)
    Ph.D., Interim Chief Technology Officer
  • Dr. Stewart Abbot Ph.D. (Age 56)
    Chief Scientific Officer
  • Mr. P. Joseph Campisi Jr. (Age 62)
    Esq., J.D., M.B.A., Chief Legal Officer














TSBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Turnstone Biologics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turnstone Biologics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSBX shares.
View TSBX analyst ratings
or view top-rated stocks.

What is Turnstone Biologics' stock price target for 2024?

4 brokers have issued 1 year target prices for Turnstone Biologics' shares. Their TSBX share price targets range from $18.00 to $20.00. On average, they expect the company's share price to reach $19.00 in the next year. This suggests a possible upside of 601.1% from the stock's current price.
View analysts price targets for TSBX
or view top-rated stocks among Wall Street analysts.

How have TSBX shares performed in 2023?

Turnstone Biologics' stock was trading at $11.00 at the beginning of the year. Since then, TSBX stock has decreased by 75.4% and is now trading at $2.71.
View the best growth stocks for 2023 here
.

When is Turnstone Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our TSBX earnings forecast
.

How were Turnstone Biologics' earnings last quarter?

Turnstone Biologics Corp. (NASDAQ:TSBX) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.33.

When did Turnstone Biologics IPO?

(TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at a price of $12.00 per share.

When does Turnstone Biologics' lock-up period expire?

Turnstone Biologics' lock-up period expires on Wednesday, January 17th. Turnstone Biologics had issued 6,666,667 shares in its IPO on July 21st. The total size of the offering was $80,000,004 based on an initial share price of $12.00. After the expiration of Turnstone Biologics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Turnstone Biologics' major shareholders?

Turnstone Biologics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (12.39%), Eventide Asset Management LLC (3.10%), Sectoral Asset Management Inc. (2.27%), Northern Trust Corp (0.25%), New York State Common Retirement Fund (0.08%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Rishi Gupta and Versant Ventures V, Llc.
View institutional ownership trends
.

How do I buy shares of Turnstone Biologics?

Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TSBX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -